A Phase 1/2 interventional study of Placebo and Baminercept in Secondary Progressive Multiple Sclerosis, sponsored by Biogen. Withdrawn. Open to participants aged 18 Years to 57 Years. Per ClinicalTrials.gov, last updated 2013-09-16.
Sponsored by Biogen · Phase 1/2, Interventional, and Treatment
This is a prospective, randomized, multicenter, dose escalation study to determine subject safety, pharmacokinetic, and pharmacodynamic responses in patients with SPMS
This study is a prospective, randomized, placebo-controlled, blinded, dose escalation study of 3 to 4 cohorts with defined number of patients per cohort receiving active drug or placebo for a period of 4 months followed by safety monitoring for an additional 4 months after the last dose
3,517 studies on the registry are indexed under Neoplasm Metastasis; 884 are open to participants now.
Browse Neoplasm Metastasis studies →Biogen is the lead sponsor of 494 studies on the registry; 22 are open to participants now.
Of its 98 completed or terminated interventional studies of FDA-regulated products, 49 (50%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Measure: Change in cerebrospinal fluid levels of secondary lymphoid organs chemokines from baseline with baminercept relative to placebo
Time frame: after 4 months of treatment
Number of subjects experiencing Serious Adverse Event (SAE) and Adverse Event (AE) with baminercept relative to placebo
Time frame: 8 months (4 months on drug, 4 months post-drug)
No study locations are listed for this record.
This study is withdrawn, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Biogen